• "Lady", an 11-year-old female dog was presented to Innocan labs suffering from severe autoimmune mediated polyarthritis.

• Lady was treated with Glycoflex, steroids, and hydrotherapy, but still suffered pain and had difficulty walking more than a few steps.

• Lady was administered Innocan's liposomal CBD injection and experienced significant improvement, which lasted more than five weeks, indicating the long-acting nature of the liposomal CBD formulation.

Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - February 21, 2023) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary IP portfolio, is pleased to report another clinical success in its Canine (dogs) Compassionate Care Trial, resulting in improving walking abilities and significant decrease in pain in participating canines.

"Lady", an 11-year-old spayed dachshund-mixed dog was suffering from severe autoimmune mediated polyarthritis that resulted in an almost complete inability to walk, accompanied by severe pain and an overall disability.

Figure 1 "Lady"

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/6922/155502_6846c17cc43a8ba8_001full.jpg

Cannot view this video? Visit:
https://www.youtube.com/watch?v=MGm4GANhqUU

Lady was treated with joint supplements (Glycoflex), steroids, and hydrotherapy, but was still very lame and incapable of walking more than a few steps. In December 2022, as part of the Company's Compassionate Care Trial, Lady was administered Innocan's liposomal CBD injection, in addition to all other treatments. Following injection, Lady demonstrated noticeable improvement, walking longer distances and much faster than she had been previously. The improvement in Lady's condition lasted for more than five weeks, indicating the long-acting nature of the liposomal CBD formulation.

"We couldn't be more thrilled than to be able to assist a poor creature in pain," said CEO Iris Bincovich, "2023 started with rapid clinical and IP performance, igniting the hope that we are getting closer to advanced availability of treatments. We believe that our ability to help Lady will also contribute to our ability to bring CBD-based pharma solutions to the market."

About Innocan

Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients' quality of life. This segment involves two drug delivery technologies: (i) LPT CBD- loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. (ii) CLX CBD-loaded exosomes platform that may hold the potential to provide a highly synergistic effect of regenerating and anti- inflammatory properties targeting the Central Nervous System (CNS). In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales. https://innocanpharma.com/